Actemra ACTPen
Actemra ACTPen ingredients
| Active ingredient | Strength |
|---|---|
| Tocilizumab | 162 mg/.9mL |
What Actemra ACTPen is used for
The FDA lists the approved uses on the official label (below). In the EU, tocilizumab is approved as RoActemra for:
RoActemra, in combination with methotrexate (MTX), is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Actemra ACTPen
- Generic name
- Tocilizumab
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Interleukin-6 Receptor Antagonist
- FDA approval
- Biologic licence (BLA) BLA125472
- On the US market since
- 2018
Official information
- Actemra ACTPen prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tocilizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Actemra ACTPen?
Actemra ACTPen (Tocilizumab) is a specialist medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Actemra ACTPen?
Actemra ACTPen contains Tocilizumab (162 mg/.9mL).
Is Actemra ACTPen approved in Europe?
The same active substance is approved in the EU as RoActemra.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA